{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.2","upperLimit":"97.2","value":"71.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Bortezomib, Ixazomib"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.0","upperLimit":"108.4","value":"87.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"Carfilzomib, Ixazomib"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.0","upperLimit":"108.4","value":"83.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Bortezomib/Carfilzomib, Ixazomib"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.0","upperLimit":"100.4","value":"47.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Lenalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.6","upperLimit":"105.3","value":"48.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Dexamethasone"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"RDI for each study drug is defined as 100\\*(Total amount of dose taken)/(Total prescribed dose of treated cycles), where total prescribed dose equals \\[dose prescribed at enrollment\\* number of prescribed doses per cycle\\* the number of treated cycles\\].","dispersionType":"Full Range","groups":[{"description":"Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG000","title":"[Overall]; Combination Therapy + Ixazomib Therapy"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): all participants who were enrolled in Treatment Period I and who receive at least one dose of any therapy during the Treatment Period.","reportingStatus":"POSTED","timeFrame":"Up to 39 months as a maximum","title":"Relative Dose Intensity (RDI)","type":"SECONDARY","unitOfMeasure":"Percent"}